Eli Lilly and Company (LLY) : $63.2 million worth of transactions were on upticks in Eli Lilly and Company (LLY), compared to $43.04 million on downticks. The ratio between the two was 1.47, whereas, the net money flow stood at a healthy $20.16 million on Thursdays session.The block trades show a bullish bias with only $3.43 million worth of transactions done on downticks. The consistent buying on upticks in the stock accounted for $26.67million worth of trades. The up-down ratio between the uptick and downtick was 7.77, confirming that the stronger hands have been buying the stock on every weakness. The total money flow into the stock stood at $23.24 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.87%. The stock was trading at $79.32, with a drop of $0.7 over the previous days close. The stock recorded 0.47% for the week.
Eli Lilly and Company (LLY) : 12 Wall Street analysts covering Eli Lilly and Company (LLY) believe that the average level the stock could reach for the short term is $94.58. The maximum price target given is $116 and the minimum target for short term is around $55, hence the standard deviation is calculated at $15.96. The stock has recorded a 20-day Moving Average of 5.34% and the 50-Day Moving Average is 5.24%.
Eli Lilly and Company (NYSE:LLY): The stock opened at $79.83 on Thursday but the bulls could not build on the opening and the stock topped out at $80.05 for the day. The stock traded down to $78.65 during the day, due to lack of any buying support eventually closed down at $79.32 with a loss of -0.87% for the day. The stock had closed at $80.02 on the previous day. The total traded volume was 3,587,328 shares.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.